Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Direct-Acting Antiviral Therapy on Renal Function in Chronic Hepatitis C
2016-005081-60Phase 4Terminated
- Sponsor
- Jose Luis Calleja Panero
- Start
- Mar 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of sofosbuvir, ledipasvir, ombitasvir, paritaprevir, ritonavir and 4 more in hepatitis C virus infection, sponsored by Jose Luis Calleja Panero. Primary endpoint: Glomerular filtration according to CKD-EPI. Started Mar 2017; status: terminated.
02
Drugs
sofosbuvirledipasvirombitasvirparitaprevirritonavir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2016-005081-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005081-60.